On appeal of a PTAB decision that all claims in a patent on compressing video files were unpatentable, the Federal Circuit clarified two issues. This post considers the second addressed issue – is the...
(as published by Law360) The U.S. Court of Appeals for the Federal Circuit recently highlighted an important rule of patent claim construction: that claim limitations should be construed in a way that...
On appeal of a PTAB decision finding all claims in a patent directed to compressing video files unpatentable, the Federal Circuit clarified two issues. This post considers the first clarified issue – ...
(as published by IPWatchdog) “Many startups make the mistake of ignoring the value of non-patent intellectual property…. A company’s brand can be immensely valuable in the marketplace.”
(as published by Law360) As we round the corner into a second year of the COVID-19 pandemic, many of us are not back in our offices, and working from home has become the new normal. While the challeng...
John Welch co-authored an article published by World Trademark Review titled "Where to Appeal a TTAB Decision? The Choice is Complicated." Read more (subscription required).
An article co-authored by John Strand titled “Does the Buck(eye) Stop Here? Sixth Circuit Reinstates Ohio State Trademark Claims,” was featured in World Trademark Review. Read more (subscription requi...
The time bar in Section 315(b) says that IPR may not be instituted if the petition was filed more than one year after the petitioner was “served with a complaint alleging infringement of the patent.” ...
(as published in the May 2021 issue of the American Chemical Society's Northeast Section publication of The Nucleus)
Roughly a year after lockdowns occurred nationwide, its impact on the country’s federal court system is still being felt. While the strain of the pandemic and its attendant restrictions are universall...
Jonathan Roses was the lead author on behalf of the Boston Patent Law Association’s (BPLA’s) Patent Office Practice and Licensing Committees of an April 2021 Response to a Notice of Proposed Rulemakin...
On February 11, 2021 the Federal Circuit upheld a United States District Court for the District of Delaware decision finding that Amgen’s function-only anti-PCSK9 monoclonal antibody claims were noten...